Compare STSS & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STSS | GRML |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | 55 | 5 |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 51.5M |
| IPO Year | N/A | 2022 |
| Metric | STSS | GRML |
|---|---|---|
| Price | $1.84 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 246.3K | ★ 3.0M |
| Earning Date | 04-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $0.27 |
| 52 Week High | $18.23 | $0.55 |
| Indicator | STSS | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 47.21 | 46.43 |
| Support Level | $1.66 | $0.31 |
| Resistance Level | $2.00 | $0.43 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 18.75 | 27.24 |
Sharps Technology Inc is a medical device and pharmaceutical packaging company offering patented, smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities that incorporate syringe technologies that use both passive and active safety features. The Company has adopted a digital asset treasury scheme focused on accumulating SOL, the native digital asset of the Solana blockchain, leveraging capital markets raises to power on-chain yield generation with the Solana Ecosystem.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.